FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Secondary benefit of weight loss

Achieve the secondary benefit of weight loss with FORXIGA® 10 mg added to metformin12,16*

FORXIGA® offers the additional secondary benefit of weight loss
FORXIGA® offers the additional secondary benefit of weight loss

*FORXIGA® is not indicated for weight loss. Weight change was a secondary endpoint in clinical trials.1